Share this article
Share this article
SOUTH EASTON, Mass., Dec. 17, 2020 /PRNewswire/ Pressure BioSciences, Inc. (OTCQB: PBIO) ( PBI or the Company ), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmetics, nutraceuticals, and food & beverage industries, today announced a remarkable convergence of global research teams announcing pivotal new insights into COVID-19 biology and disease processes. These data point to potential new pathways to next generation diagnostics and treatments. All teams selected PBI s Pressure Cycling Technology ( PCT ) platform for their critical sample preparation steps, to help ensure that the greatest abundance and diversity of reproducible results would be revealed in the thousands of proteins involved in the affected biochemical pathways.